CLIC3 emerges as a novel prognostic biomarker and therapeutic target in triple-negative breast cancer through integrated multi-omics analysis.

ABSTRACT:

Background

Triple-negative breast cancer (TNBC) remains clinically challenging due to its aggressiveness, limited targeted therapies, and absence of reliable prognostic biomarkers. Identifying TNBC-specific molecular drivers is critical for improving patient outcomes.

Methods

We employed an integrated multi-omics approach to analyze tumor and adjacent normal tissues from 4 TNBC and 4 non-TNBC patients via RNA sequencing (RNA-seq) and whole-exome sequencing (WES), complemented by an extensive analysis of 115 TNBC and 976 non-TNBC samples from The Cancer Genome Atlas (TCGA). Prognostic screening was performed to identify potential biomarkers correlated with patient survival. In vitro experimental validation was carried out in MDA-MB-231 TNBC cells, and immunohistochemistry was

SUBMITTER: Yuan S 

PROVIDER: S-EPMC12659645 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature